This database contains 10 studies, archived under the term: "Movement Disorders: Official Journal Of The Movement Disorder Society"
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study
Mild cognitive impairment (MCI) in Parkinson’s disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal […]
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease
We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington’s disease, with additional evaluation of its safety and tolerability. This was a randomized, double-blind, placebo-controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty-seven subjects enrolled from […]
Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study
Dubois, Bruno,
Tolosa, Eduardo,
Katzenschlager, Regina,
Emre, Murat,
Lees, Andrew J.,
Schumann, Günther,
Pourcher, Emmanuelle,
Gray, Julian,
Thomas, Gail,
Swartz, Jina,
Hsu, Timothy,
Moline, Margaret L.
Parkinson’s disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and […]
Levodopa use and sleep in patients with dementia with Lewy bodies
Sleep disturbance and excessive daytime somnolence (EDS) are features of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) that may be influenced by dopamine replacement therapy. The effect of levodopa on sleep and EDS in DLB is unknown and unclear in PD. The aim of this study is to determine if levodopa treatment alters […]
Randomized controlled trial of memantine in dementia associated with Parkinson’s disease
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson’s disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 […]
A pilot study using nabilone for symptomatic treatment in Huntington’s disease
Pilot study of nabilone in Huntington’s disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington’s Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = […]
Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine
Brusa, Livia,
Orlacchio, Antonio,
Moschella, Vincenzo,
Iani, Cesare,
Bernardi, Giorgio,
Mercuri, Nicola Biagio
Aripiprazole (AP), a dopamine (DA) D(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington’s disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare […]
Results of the citalopram to enhance cognition in Huntington disease trial
Beglinger, Leigh J.,
Adams, William H.,
Langbehn, Douglas,
Fiedorowicz, Jess G.,
Jorge, Ricardo,
Biglan, Kevin,
Caviness, John,
Olson, Blair,
Robinson, Robert G.,
Kieburtz, Karl,
Paulsen, Jane S.
Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington’s disease (HD).; Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and […]